The U.S. FDA has granted priority review to J&J's Janssen Pharmaceuticals' new drug application for antipsychotic Invega Trinza.
Invega Trinza is a three-month injection administered four times a year, offering the longest dosing interval available for schizophrenia patients. Patients must first be treated with Invega Sustenna, a once-monthly injection, for at least four months before undergoing treatment.
According to a study published by the companies in March, 93% of patients in a long-term maintenance trial treated with Invega Trinza didn't experience a significant return of schizophrenia symptoms.
Read the WSJ article